Concise review of the cytochrome P450s and their roles in toxicology

Toxicological Sciences

Volumn 48, Issue 2, 1999, Pages 151-156

  Omiecinski, Curtis J ^a   Remmel, Rory P ^b   Hosagrahara, Vinayak P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; CLOZAPINE; CODEINE; CYTOCHROME P450 ISOENZYME; DIAZEPAM; DICLOFENAC; ENCAINIDE; FELBAMATE; IBUPROFEN; LOSARTAN; MEFENAMIC ACID; METOPROLOL; METYRAPONE; MEXILETINE; NAPROXEN; OMEPRAZOLE; ONDANSETRON; ORGANIC COMPOUND; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PROGUANIL; PROPRANOLOL; RETINOIC ACID; RIFAMPICIN; TIMOLOL; TOLBUTAMIDE; TRAMADOL; UNINDEXED DRUG; XENOBIOTIC AGENT;

ENZYME ANALYSIS; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PROTEIN FAMILY; REVIEW; TOXICOLOGY; XENOBIOTIC METABOLISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 0032911542     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/48.2.151     Document Type: Review

References (35)

1. Buters, J. T., Tang, B. K., Pineau, T., Gelboin, H. V., Kimura, S., and Gonzalez, F. J. (1996). Role of CYP1A2 in caffeine pharmacokinetics and metabolism: Studies using mice deficient in CYP1A2. Pharmacogenetics 6, 291-296.
2. Code, E. L., Crespi, C. L., Penman, B. W., Gonzalez, F. J., Chang, T. K., and Waxman, D. J. (1997). Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 25, 985-993.
3. Crofts, F. G., Strickland, P. T., Hayes, C. L., and Sutter, T. R. (1997). Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by human cytochrome P4501B1. Carcinogenesis 18, 1793-1798.
4. Daly, A. K. (1995). Molecular basis of polymorphic drug metabolism. J. Mol. Med. 73, 539-553.
5. Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U. A., Nebert, D. W., Steen, V. M., Wolf, C. R., and Zanger, U. M. (1996). Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6, 193-201.
6. Dogra, S. C., Whitelaw, M. L., and May, B. K. (1998). Transcriptional activation of cytochrome P450 genes by different classes of chemical inducers. Clin. Exp. Pharmacol. Physiol. 25, 1-9.
7. Eaton, D. L., Gallagher, E. P., Bammler, T. K., and Kunze, K. L. (1995). Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmacogenetics 5, 259-274.
8. Ekins, S., Vandenbranden, M., Ring, B. J., and Wrighton, S. A. (1997). Examination of purported probes of human CYP2B6. Pharmacogenetics 7, 165-179.
9. Fernandez-Salguero, P., and Gonzalez, F. J. (1995). The CYP2A gene subfamily: Species differences, regulation, catalytic activities, and role in chemical carcinogenesis. Pharmacogenetics 5, S123-S128.
10. Gallagher, E. P., Kunze, K. L., Stapleton, P. L., and Eaton, D. L. (1996). The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol. Appl. Pharmacol. 141, 595-606.
11. Gonzalez, F. J. (1997). The role of peroxisome proliferator activated receptor alpha in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis. Adv. Exp. Med. Biol. 422, 109-125.
12. Gonzalez, F. J., and Gelboin, H. V. (1994). Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 26, 165-183.
13. Gonzalez, F. J., Liu, S. Y., and Yano, M. (1993). Regulation of cytochrome P450 genes: Molecular mechanisms. Pharmacogenetics 3, 51-57.
14. Guengerich, F. P., Humphreys, W. G., Yun, C. H., Hammons, G. J., Kadlubar, F. F., Seto, Y., Okazaki, O., and Martin, M. V. (1995). Mechanisms of cytochrome P450 1A2-mediated formation of N-hydroxy arylamines and heterocyclic amines and their reaction with guanyl residues. Princess Takamatsu Symp. 23, 78-84.
15. Lee, S. S., Buters, J. T., Pineau, T., Fernandez-Salguero, P., and Gonzalez, F. J. (1996). Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 271, 12063-12067.
16. Li, Y., Li, N. Y., and Sellers, E. M. (1997). Comparison of CYP2A6 catalytic activity on coumarin 7-hydtoxylation in human and monkey liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 22, 295-304.
17. Lieber, C. S. (1997). Cytochrome P-4502E1: Its physiological and pathological role. Physiol. Rev. 77, 517-544.
18. Meyer, U. A., and Zanger, U. M. (1997). Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296.
19. Mimura, M., Baba, T., Yamazaki, H., Ohmori, S., Inui, Y., Gonzalez, F. J., Guengerich, F. P., and Shimada, T. (1993). Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab. Dispos. 21, 1048-1056.
20. Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F., and Kamataki, T. (1994). Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: Absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol. Biomarkers Prev. 3, 413-421.
21. Nebert, D. W. (1997) Polymorphisms in drug-metabolizing enzymes: What is their clinical relevance and why do they exist? Am. J. Hum. Genet. 60, 265-271 (editorial; comment).
22. Nebert, D. W., and McKinnon, R. A. (1994). Cytochrome P450: Evolution and functional diversity. Prog.Liver Dis. 12P, 63-97.
23. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C., and Nebert, D. W. (1996). P450 superfamily: Update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 6, 1-42.
24. Omura, T., and Sato, R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J.Biol.Chem. 239, 2370-2378.
25. Ono, S., Hatanaka, T., Hotta, H., Tsutsui, M., Satoh, T., and Gonzalez, F. J. (1995). Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5, 143-150.
26. Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., and Johnson, E. F. (1998). Peroxisome proliferator activated receptor-alpha expression in human liver. Mol. Pharmacol. 53, 14-22.
27. Parkinson, A. (1996). Biotransformation of xenobiotics. In Casarett & Doull's Toxicology: The Basic Science of Poisons, 5th ed. (C. D. Klaassen, Ed.), pp. 113-186. McGraw-Hill, New York.
28. Pelkonen, O., and Raunio, H. (1997) Metabolic activation of toxins: Tissue-specific expression and metabolism in target organs. Environ. Health Perspect. 105(suppl.4), 767-774.
29. Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J., and Harris, J. W. (1994). Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543-5546.
30. Rendic, S., and Di-Carlo, F. J. (1997). Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29, 413-580.
31. Simpson, A. E. (1997). The cytochrome P450 4 (CYP4) family. Gen. Pharmacol. 28, 351-359.
32. Steward, D. J., Haining, R. L., Henne, K. R., Davis, G., Rushmore, T. H., Trager, W. F., and Rettie, A. E. (1997). Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7, 361-367.
33. Thummel, K. E., and Wilkinson, G. R. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430.
34. Wilkinson, G. R. (1996). Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J. Pharmacokinet. Biopharm. 24, 475-490.
35. Yang, T. J., Shou, M., Korzekwa, K. R., Gonzalez, F. J., Gelboin, H. V., and Yang, S. K. (1998). Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem. Pharmacol. 55, 889-896.